Lilly: Axiron improves hypogonadism symptoms among men
INDIANAPOLIS — A topical drug made by Eli Lilly restored testosterone to normal levels in men with abnormally low testosterone, according to results of a late-stage clinical trial.
Lilly announced results of a phase-3 trial of Axiron (testosterone) topical solution, a treatment for the condition, also known as hypogonadism. Study results also showed that the drug improved symptoms associated with it.
Hypogonadism results from damage or disease of the testicles, hypothalamus or pituitary glands that inhibits production of testosterone.
Tris Pharma names VP human resources
MONMOUTH JUNCTION, N.J. — A specialty pharmaceutical company has appointed a new VP human resources.
Cheryl Patnick, who has more than 20 years of experience in human resources and mergers/acquisitions, will lead and manage Tris Pharma’s human resource activities, the company said Wednesday.
"Tris is at a point in its evolution where it needs leaders who are willing to take charge of the increasing demands of a rapidly growing company while concurrently supporting the culture that has led to its growth," Tris Pharma president and CEO Ketan Mehta said. "Cheryl, who has been working with me for more than a year, is one such leader. We are fortunate to have her joining us in this strategically important position."
NACDS proposes ‘one-document solution’ for medication info to the FDA
ALEXANDRIA, Va. — The Obama administration recently called on the public for ideas to streamline federal regulations. In response, the National Association of Chain Drug Stores has sent its suggestion to the Food and Drug Administration.
In a letter submitted to FDA commissioner Margaret Hamburg on Monday, NACDS told the agency that it should focus on streamlining patient medication information, or PMI. Currently, the FDA requires pharmacies to provide patients with several different types of information on prescription medications, including medication guides, patient package inserts and consumer medication information, NACDS said. Often, the information is penned by several authors and therefore may be too complex for patients to comprehend.
To mitigate this, NACDS suggested that the FDA implement a "one-document solution," which would "provide patients with useful and focused information on their prescription medications and allow pharmacies to advise and counsel patients on adhering to prescription medication," the organization wrote.
"We urge the FDA to elevate the transition from medication guides, patient package inserts and other consumer medication information to the ‘one-document solution’ PMI to be among the FDA’s highest priorities,” NACDS said.
NACDS first proposed a "one-document solution" for PMI in 2007.